Organisation paid for research Program year 2025 Source: CMS Open Payments

Arthritis Northwest PLLC

Neither a doctor nor a teaching hospital

Research payments

$4,046,939

548 payments

Through program year 2025, Arthritis Northwest PLLC is reported as receiving $4,046,939 in research payments, across 548 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,854,811 88
2024 Research $628,680 46
2023 Research $132,500 66
2022 Research $189,459 79
2021 Research $170,221 68
2020 Research $370,171 97
2019 Research $701,097 104

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $2,247,519 4 payments
  2. AbbVie, Inc. $493,200 149 payments
  3. Novartis Pharmaceuticals Corporation $305,254 11 payments
  4. Eli Lilly and Company $268,248 47 payments
  5. GlaxoSmithKline, LLC. $212,117 18 payments
  6. Sun Pharmaceutical Industries Inc. $167,662 163 payments
  7. Ascendis Pharma, Inc. $98,953 74 payments
  8. Ucb SA $92,870 16 payments
  9. Pfizer Inc. $63,286 35 payments
  10. Gilead Sciences, Inc. $47,702 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $1,707,065 1 payment
  2. P4 Uncontrolled Gout FORWARD II $539,290 2 payments
  3. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, $211,183 15 payments
  4. A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $129,187 2 payments
  5. M15-572 $124,870 26 payments
  6. Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) $108,748 88 payments
  7. M15-998 $108,724 13 payments
  8. A Multicenter Long-Term Extension Study of 104 Weeks Including A Double Blind Placebo Controlled 40 Week Randomized Withdrawal Retreatment Period to Evaluate the Maintenance of Treatment Effect of Ixekizumab Ly2439821 in Patients With Axial Spondyloarthritis $66,358 6 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis $65,790 6 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Ankylosing Spo $53,168 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $37,580 30 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record